Abstract: BACKGROUND: Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether pegylated interferon alfa-2b can facilitate prolonged exposure while maintaining tolerability. METHODS: 1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627) 6 mug/kg per week for 8 weeks (induction) then 3 mug/kg per week (maintenance) for an intended duration of 5 years. Randomisation was stratified for microscopic (N1) versus macroscopic (N2) nodal involvement, number of positive nodes, ulceration and tumour thickness, sex, and centre. Randomisation was done with a minimisation technique. The primary endpoint was recurrence-free survival. Analyses were done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00006249. FINDINGS: All randomised patients were included in the primary efficacy analysis. 608 patients in the interferon group and 613 patients in the observation group were included in safety analyses. The median length of treatment with pegylated interferon alfa-2b was 12 (IQR 3.8-33.4) months. At 3.8 (3.2-4.2) years median follow-up, 328 recurrence events had occurred in the interferon group compared with 368 in the observation group (hazard ratio 0.82, 95% CI 0.71-0.96; p=0.01); the 4-year rate of recurrence-free survival was 45.6% (SE 2.2) in the interferon group and 38.9% (2.2) in the observation group. There was no difference in overall survival between the groups. Grade 3 adverse events occurred in 246 (40%) patients in the interferon group and 60 (10%) in the observation group; grade 4 adverse events occurred in 32 (5%) patients in the interferon group and 14 (2%) in the observation group. In the interferon group, the most common grade 3 or 4 adverse events were fatigue (97 patients, 16%), hepatotoxicity (66, 11%), and depression (39, 6%). Treatment with pegylated interferon alfa-2b was discontinued because of toxicity in 191 (31%) patients. INTERPRETATION: Adjuvant pegylated interferon alfa-2b for stage III melanoma has a significant, sustained effect on recurrence-free survival. 
Introduction
Interferon (IFN)α-2b is the most investigated agent for adjuvant treatment of patients with stage IIb (primary tumor ≥ 4 mm, node-negative) and stage III (any primary tumor, node-positive) melanoma, both groups at high risk of recurrence after definitive surgery. (1) Results from multiple controlled trials suggest that the role of an induction period, the optimum dose and duration for adjuvant interferon α in high-risk melanoma remain to be defined. interval (DMFI) (P=0.029, borderline significant), while the intermediate-dose, 13-month regimen had no effect on DMFI, suggesting longer duration of treatment with lower doses may be more effective than shorter-term therapy at higher doses. (7) By enabling prolonged, weekly self-administered adjuvant therapy, pegylated interferon α-2b (PEG-IFNα-2b) has the potential to improve the benefit-toxicity balance for patients with resected stage III melanoma. Therapy with PEG-IFNα-2b has been shown to maintain maximal exposure to interferon α-2b for 48 to 72 hours, with a measurable residual trough level, compared with rapid decline from peak plasma concentrations for unpegylated IFNα-2b in patients with chronic hepatitis C, allowing once-weekly rather than three-times weekly subcutaneous (sc) injections. (13) EORTC 18991 clinical trial here reported is a randomised phase 3 controlled study of adjuvant therapy conducted in stage III melanoma, where the efficacy and toxicity of PEG-IFNα-2b were compared with observation. The rationale was to provide a selfadministered treatment with prolonged exposure, for maximum of 5 years. The study was designed to allow dose reductions to maintain ECOG performance status at a score of 0 to 1 throughout the course of treatment.
The study of 1256 patients, was designed to measure an improvement in distant metastasis-free survival (DMFS) so that treatment could be continued in the event of local or regional relapse. In prior consultation with the European regulatory authorities and at the request of the United States Food and Drug Administration, the endpoint was revised prior to trial analysis to relapse-free survival (RFS), defined as the length of time from randomisation to the first of local regional or distant recurrence of melanoma or death of any cause. Secondary endpoints of the study included DMFS, overall survival Page 6 of 35 6 (OS), and safety. The results reported here are the final analysis, and the planned 10-year survival follow-up is ongoing.
Patients
Patients 18 to 70 years of age with histologically documented stage III melanoma (TxN1-2M0) were enrolled.(1) The primary cutaneous melanoma must have been completely excised with adequate surgical margins and complete regional lymphadenectomy must have occurred 70 days or less before randomisation. Patients were required to have adequate hepatic, renal, and bone marrow function before enrollment. Exclusion criteria for this study included ocular or mucous membrane melanoma, evidence of distant metastasis or in-transit metastasis, prior malignancy within the past 5 years (other than surgically resected non-melanoma skin cancer or cervical carcinoma in situ), autoimmune disease, uncontrolled infections, cardiovascular disease, liver or renal disease, use of systemic corticosteroids, and prior systemic therapy for melanoma. All patients provided written informed consent before randomisation. The following criteria to defined disease sub-stage were used: only microscopic, non-palpable nodal involvement (including those staged with sentinel node biopsy) or clinically palpable nodal involvement (synchronous with removal of the primary tumor or discovered after prior removal of the primary tumor). The protocol was approved by the EORTC protocol review committee and the local institutional ethical committees.
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Study design
Patients were randomly assigned in a 1:1 ratio to one of 2 groups: pegylated interferon α- Pegylated interferon α-2b was administered at 6 µg/kg/wk subcutaneously (sc) for 8 weeks (induction), followed by 3 µg/kg/wk sc (maintenance) for an intended treatment duration of 5 years. Stepwise dose adjustments (6 µg/kg/wk to 3, 2, and 1 µg/kg/wk during the induction phase and from 3 µg/kg/wk to 2 and 1 µg/kg/wk during the maintenance phase) of pegylated interferon α-2b were specified by the study protocol to adjust for toxicity and in order to maintain an ECOG performance status of 0 or 1 for each patient. Treatments could be interrupted for surgery for local or regional recurrence of melanoma, then resumed after surgery.
Efficacy evaluation
Patients in both arms of the study were evaluated for recurrence and distant metastases every 3 months during the first 3 years and every 6 months thereafter. Physical examination, chest radiography, computed tomography, and other imaging techniques were employed as clinically indicated. Recurrence or metastatic lesions were confirmed pathologically. The primary endpoint of the study was recurrence-free survival (RFS),
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8 defined as time from randomisation to any local or regional recurrence, distant metastasis, or death for any reason. Secondary endpoints included distant metastasis-free survival (DMFS), defined as time from randomisation to any distant metastasis or death for any reason, and overall survival (OS), defined as time from randomisation to death.
An Independent Review Committee used a blinded review process to determine the dates of events and censoring from individual patient data (= last date of disease evaluation for RFS and DMFS). These dates form the basis of the primary analysis.
Toxicity evaluation
The occurrence of adverse events was evaluated at each follow-up visit by physical examination, specific questioning of the patient, and by spontaneous reports. All reported adverse events were graded according to the Common Toxicity Criteria version 2·0. (16) Hematological and laboratory parameters were evaluated at each visit and also as clinically indicated.
Statistical analysis
The sample size was calculated to be at least 1200 patients in order to observe approximately 576 distant metastases or deaths. With 576 events the study would have approximately 90% power to detect a hazard ratio of 0.76 for DMFS, or a 9.75% difference (from 40% to 49.75%) at 4 years. formula. (18) The Cox proportional hazards model was used to obtain the hazard ratio for the treatment comparison -event rate in the PEG-IFNα-2b group versus the event rate in the observation group -and its 95% confidence interval (CI), adjusted for all factors used at randomisation. For subgroup analyses, the treatment comparison was considered to be significant at the 1% level, and therefore, the 99% CI of the hazard ratio was computed.
All efficacy analyses were based on the intent-to-treat population, whereas for toxicity analysis only patients who started the treatment/observation allocated by randomisation and were documented regarding adverse events were included. 
Patient characteristics
The median age of the study population was 50 years, with 11% of patients over 65 years ( Table 1) 
Efficacy Overall treatment results and comparisons
After a median 3.8 years of follow-up, a total of 696 recurrences or deaths had occurred:
328 in PEG-IFNα-2b and 368 in observation arm ( Table 2) Results for DMFS in the whole population were consistent with those for RFS without reaching statistical significance ( Table 2 and Figure 2B ). The difference in the median time to DMFS was similar to that observed for RFS, at 9 months (44 months in the PEG-IFNα-2b arm and 36 months in the observation arm). A total of 629 distant metastases or deaths occurred: 304 vs 325. There was a 2.8% difference in the 4-year DMFS rates:
estimated 4-year rates of DMFS were 48.2% and 45.4% for the treatment and observation arms, respectively.
Overall survival was not significantly different (P=0.78) between the 2 treatment groups:
the estimated 4-year overall survival rate was 56.8% in the PEG-IFNα-2b arm and 55.7%
in the observation arm ( Table 2 and Figure 2C ).
Subgroup analysis
The benefits of treatment with PEG-IFNα-2b are more pronounced in patients with earlier Stage III melanoma disease than in those with later stage disease ( Kaplan-Meier curves patients with one lymph node involvement showed that the benefit of treatment with pegylated interferon α-2b began quite early in the study and was maintained throughout the study. The 4-year rate treatment benefit was 11.2% (99% CI 0.4%-22.0%), 9.5% and 5.8% regarding RFS, DMFS and OS respectively ( Table 4 ).
In patients with lowest tumor burden (microscopic nodal involvement of only one node),
194 (PEG-IFNα-2b) vs 188 (observation), the treatment difference was significant for RFS (hazard ratio 0.64, 99% CI 0.42-0.98; P=0.006) and DMFS (hazard ratio 0.63, 99%
CI 0.40-1.00; P=0.009), but not for OS (hazard ratio 0.76, 99% CI 0.44-1.30; p=0.18).
The estimated improvement in 4-year rates was 14.6% (99% CI -0.1%-29.3%), 11.7% and 7.3% respectively for these 3 endpoints ( Table 5 ).
In the subgroup of patients with any number of microscopic nodal involvement and who had an ulceration in the primary tumor the impact of PEG-IFNα-2b was significant or Table 5 ). This was not the case in those with microscopic nodal involvement and who had non-ulcerated primary (data not shown).
Toxicity and cause of death: treatment comparison
Adverse events of any severity that were recorded in more than 4% of patients in the PEG-IFNα-2b and observation arms are shown in Table 6 . NCI-CTC grade 3 events Such meta-analysis will allow to check the consistency of our findings in subgroups.
Markers of patients likely to respond to interferon are needed, and this trial 18991
indicates that the combination of low tumour volume and an ulcerated primaty may be such a marker. This observation requires confirmation, and also investigation to establish its biological basis. In EORTC 18991 we cannot confirm the observation of Gogas and Abbreviations: PegIFN α-2b, pegylated interferon α-2b; Obs, observation; NR, not reached; HR, hazard ratio; CI, confidence interval 189 356  304  226  151  67  12  182 357  288  223  165  70  12 p=0.91
Observation PEG-IFNα-2b
